Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol

International Heart Journal

Volumn 54, Issue 1, 2013, Pages 15-22

  Mori, Yoshihiro ^a   Nishikawa, Yasuhiro ^a   Kobayashi, Fumiaki ^a   Hiramatsu, Katsutoshi ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Beta blocker; Observational study; Post marketing surveillance; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

AGED; AGING; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEATH; DIZZINESS; DRUG DOSE COMPARISON; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTENSION; JAPANESE; LONGITUDINAL STUDY; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; CARBAZOLES; DRUG MONITORING; FEMALE; HEART FAILURE; HUMANS; JAPAN; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PHARMACOVIGILANCE; PROGNOSIS; PROPANOLAMINES; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STROKE VOLUME; TIME; TREATMENT OUTCOME;

EID: 84874379382     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.15     Document Type: Article

References (18)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
2. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-58.
5. Lenzen MJ, Scholteop Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214-20.
6. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84.
7. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZEHF Registry. J Am Coll Cardiol 2007; 50: 768-77.
8. Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARECARD). Circ J 2009; 73: 1893-900.
9. Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-30.
10. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 2004; 43: 317-27. (Review)
11. Philbin EF, Rocco TA Jr, Lindenmuth NW, Ulrich K, Jenkins PL. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605-13.
12. Tsutsui H, Tsuchihashi M, Takeshita A. Mortality and readmission of hospitalized patients with congestive heart failure and preserved versus depressed systolic function. Am J Cardiol 2001; 88: 530-33.
13. Smith GL, Masoudi FA, Vaccarino V, Radford MJ, Krumholz HM. Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline. J Am Coll Cardiol 2003; 41: 1510-8.
14. Lainscak M, Moullet C, Schon N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007; 122: 149-55.
15. Tsuchihashi-Makaya M, Kinugawa S, Yokoshiki H, et al. Betablocker use at discharge in patients hospitalized for heart failure is associated with improved survival. Circ J 2010; 74: 1364-71.
16. Massie BM, Nelson JJ, Lukas MA, et al. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007; 99: 1263-8.
17. Takeda Y, Fukutomi T, Suzuki S, et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol 2004; 94: 448-53.
18. Hori M, Kitabatake A, Tsutsui H, et al. Rationale and design of a randomized trial to assess the effects of beta-blocker in diastolic heart failure; Japanese Diastolic Heart Failure Study (J-DHF). J Card Fail 2005; 11: 542-7.